HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CCR9
C-C motif chemokine receptor 9
Chromosome 3 · 3p21.31
NCBI Gene: 10803Ensembl: ENSG00000173585.19HGNC: HGNC:1610UniProt: B2R734
87PubMed Papers
20Diseases
2Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneReceptor
CLINICAL
Clinical Trials
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
cell surfacecalcium-mediated signalingcell chemotaxisexternal side of plasma membranealcohol drinkingCrohn's diseaseBardet-Biedl syndromeCOVID-19
✦AI Summary

CCR9 (C-C motif chemokine receptor 9) is a G protein-coupled chemokine receptor that plays critical roles in immune cell trafficking and T cell development. CCR9 binds to its primary ligand CCL25 and mediates the recruitment of specific T cell subsets to mucosal tissues, particularly the small intestine 1. During T cell development, CCR9 guides thymus seeding progenitors to migrate to the thymus alongside CCR7, facilitating T cell maturation 2. In cancer immunotherapy, CCR9+CXCR3+CD4+ T lymphocytes are recruited to tumor beds and correlate with improved responses to PD-1 blockade therapy 3. CCR9 also regulates the migration of memory-like group 2 innate lymphoid cells (ml-ILC2s) from intestinal lamina propria to airways during asthma relapse through CCR9/CCL25 signaling 4. Clinically, CCR9 represents a promising therapeutic target, as it is expressed on >70% of T cell acute lymphoblastic leukemia (T-ALL) patients and maintained at relapse, making it suitable for CAR-T cell therapy 5. Additionally, CCR9+ B cells are enriched in IgA nephropathy patients and preferentially home to mucosal sites 6. Overall, CCR9 functions as a key regulator of immune cell migration between systemic circulation and mucosal tissues.

Sources cited
1
CCR9 binds to its primary ligand CCL25 and mediates the recruitment of specific T cell subsets to mucosal tissues, particularly the small intestine .
PMID: 28207301
2
During T cell development, CCR9 guides thymus seeding progenitors to migrate to the thymus alongside CCR7, facilitating T cell maturation .
PMID: 39257583
3
In cancer immunotherapy, CCR9+CXCR3+CD4+ T lymphocytes are recruited to tumor beds and correlate with improved responses to PD-1 blockade therapy .
PMID: 29097494
4
CCR9 also regulates the migration of memory-like group 2 innate lymphoid cells (ml-ILC2s) from intestinal lamina propria to airways during asthma relapse through CCR9/CCL25 signaling .
PMID: 39245681
5
Clinically, CCR9 represents a promising therapeutic target, as it is expressed on >70% of T cell acute lymphoblastic leukemia (T-ALL) patients and maintained at relapse, making it suitable for CAR-T cell therapy .
PMID: 40598348
6
Additionally, CCR9+ B cells are enriched in IgA nephropathy patients and preferentially home to mucosal sites .
PMID: 35115327
Disease Associationsⓘ20
alcohol drinkingOpen Targets
0.31Weak
Crohn's diseaseOpen Targets
0.30Weak
Bardet-Biedl syndromeOpen Targets
0.12Weak
COVID-19Open Targets
0.11Weak
neoplasmOpen Targets
0.11Weak
MODYOpen Targets
0.11Weak
acute lymphoblastic leukemiaOpen Targets
0.10Weak
type 1 diabetes mellitusOpen Targets
0.10Weak
rheumatoid arthritisOpen Targets
0.10Weak
colorectal carcinomaOpen Targets
0.09Suggestive
knee fractureOpen Targets
0.09Suggestive
myocardial infarctionOpen Targets
0.09Suggestive
ulcerative colitisOpen Targets
0.09Suggestive
celiac diseaseOpen Targets
0.09Suggestive
Okt4 epitope deficiencyOpen Targets
0.08Suggestive
peeling skin syndromeOpen Targets
0.08Suggestive
lung adenocarcinomaOpen Targets
0.08Suggestive
cardiac hypertrophyOpen Targets
0.08Suggestive
necrotizing enterocolitisOpen Targets
0.07Suggestive
secondary progressive multiple sclerosisOpen Targets
0.07Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets2
MLN3126Phase I
C-C chemokine receptor type 9 antagonist
Sjogren syndrome
VERCIRNONPhase III
C-C chemokine receptor type 9 antagonist
Crohn's disease
Related Genes
SELPLGProtein interaction99%CCL11Protein interaction99%CCL5Protein interaction97%CXCL10Protein interaction95%CXCL1Protein interaction94%CXCL9Protein interaction93%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
18%
Lung
13%
Liver
11%
Ovary
4%
Heart
0%
Gene Interaction Network
Click a node to explore
CCR9SELPLGCCL11CCL5CXCL10CXCL1CXCL9
PROTEIN STRUCTURE
Preparing viewer…
PDB5LWE · 2.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.99LoF Tolerant
pLIⓘ
0.26Tolerant
Observed/Expected LoF0.43 [0.21–0.99]
RankingsWhere CCR9 stands among ~20K protein-coding genes
  • #5,463of 20,598
    Most Researched87
  • #9,456of 17,882
    Most Constrained (LOEUF)0.99
Genes detectedCCR9
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Biological drug and drug delivery-mediated immunotherapy.
PMID: 33996408
Acta Pharm Sin B · 2021
1.00
2
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
PMID: 29097494
Science · 2018
0.90
3
CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.
PMID: 33076281
Int J Mol Sci · 2020
0.80
4
The thymus road to a T cell: migration, selection, and atrophy.
PMID: 39257583
Front Immunol · 2024
0.70
5
TCF-1 and TOX regulate the memory formation of intestinal group 2 innate lymphoid cells in asthma.
PMID: 39245681
Nat Commun · 2024
0.60